Lymphotoxin α revisited: general features and implications in rheumatoid arthritis
- PMID:21861866
- PMCID: PMC3239340
- DOI: 10.1186/ar3376
Lymphotoxin α revisited: general features and implications in rheumatoid arthritis
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting synovial joints. Therapies blocking tumor necrosis factor-alpha (TNFα) are now routinely used in the management of RA. However, a significant number of patients with RA do not respond or develop resistance to anti-TNF therapies, and the participation of other cytokines in RA pathogenesis has been reported as well. Lymphotoxin alpha (LTα) is the closest homolog to TNFα and has been implicated in inflammation and autoimmunity since its original description in 1968. In spite of that, little is known about the role of LTα in RA or the potential of blocking this cytokine as an alternative therapeutic approach. In this review, we aim to summarize the general features of LTα and what is currently known about its participation in RA.
Figures

Similar articles
- The role of lymphotoxin-α in rheumatoid arthritis.Hirose T, Fukuma Y, Takeshita A, Nishida K.Hirose T, et al.Inflamm Res. 2018 Jun;67(6):495-501. doi: 10.1007/s00011-018-1139-6. Epub 2018 Mar 14.Inflamm Res. 2018.PMID:29541795Review.
- Lymphotoxin α stimulates proliferation and pro-inflammatory cytokine secretion of rheumatoid arthritis synovial fibroblasts.Calmon-Hamaty F, Combe B, Hahne M, Morel J.Calmon-Hamaty F, et al.Cytokine. 2011 Feb;53(2):207-14. doi: 10.1016/j.cyto.2010.10.010. Epub 2010 Dec 15.Cytokine. 2011.PMID:21111629
- High levels of Lymphotoxin-Beta (LT-Beta) gene expression in rheumatoid arthritis synovium: clinical and cytokine correlations.O'Rourke KP, O'Donoghue G, Adams C, Mulcahy H, Molloy C, Silke C, Molloy M, Shanahan F, O'Gara F.O'Rourke KP, et al.Rheumatol Int. 2008 Aug;28(10):979-86. doi: 10.1007/s00296-008-0574-z. Epub 2008 Apr 1.Rheumatol Int. 2008.PMID:18379788
- Astroglial-derived lymphotoxin-alpha exacerbates inflammation and demyelination, but not remyelination.Plant SR, Arnett HA, Ting JP.Plant SR, et al.Glia. 2005 Jan 1;49(1):1-14. doi: 10.1002/glia.20089.Glia. 2005.PMID:15382206
- Tumour necrosis factor and lymphotoxin: molecular aspects and role in tissue-specific autoimmunity.Körner H, Sedgwick JD.Körner H, et al.Immunol Cell Biol. 1996 Oct;74(5):465-72. doi: 10.1038/icb.1996.77.Immunol Cell Biol. 1996.PMID:8912010Review.
Cited by
- Role of lymphotoxin alpha as a new molecular biomarker in revolutionizing tear diagnostic testing for dry eye disease.Li CR.Li CR.Int J Ophthalmol. 2023 Nov 18;16(11):1883-1889. doi: 10.18240/ijo.2023.11.22. eCollection 2023.Int J Ophthalmol. 2023.PMID:38028523Free PMC article.Review.
- Tertiary lymphoid structures in head and neck squamous cell carcinoma improve prognosis by recruiting CD8+ T cells.Wang M, Zhai R, Wang M, Zhu W, Zhang J, Yu M, Zhang W, Ye J, Liu L.Wang M, et al.Mol Oncol. 2023 Aug;17(8):1514-1530. doi: 10.1002/1878-0261.13403. Epub 2023 Mar 8.Mol Oncol. 2023.PMID:36825382Free PMC article.
- Pulmonary Immune Dysregulation and Viral Persistence During HIV Infection.Alexandrova Y, Costiniuk CT, Jenabian MA.Alexandrova Y, et al.Front Immunol. 2022 Jan 4;12:808722. doi: 10.3389/fimmu.2021.808722. eCollection 2021.Front Immunol. 2022.PMID:35058937Free PMC article.Review.
- Loss of Lymphotoxin Alpha-Expressing Memory B Cells Correlates with Metastasis of Human Primary Melanoma.Werner F, Wagner C, Simon M, Glatz K, Mertz KD, Läubli H, Richtig E, Griss J, Wagner SN.Werner F, et al.Diagnostics (Basel). 2021 Jul 12;11(7):1238. doi: 10.3390/diagnostics11071238.Diagnostics (Basel). 2021.PMID:34359321Free PMC article.
- Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1.Steeland S, Puimège L, Vandenbroucke RE, Van Hauwermeiren F, Haustraete J, Devoogdt N, Hulpiau P, Leroux-Roels G, Laukens D, Meuleman P, De Vos M, Libert C.Steeland S, et al.J Biol Chem. 2015 Feb 13;290(7):4022-37. doi: 10.1074/jbc.M114.617787. Epub 2014 Dec 23.J Biol Chem. 2015.PMID:25538244Free PMC article.
References
- Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. 1990;33(Suppl 3):305–315. - PubMed
- Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL. on behalf of the British Society for Rheumatology Biologics Register. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70:583–589. doi: 10.1136/ard.2010.139774. - DOI - PMC - PubMed
- Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med. 2004;350(Suppl 21):2167–2179. - PubMed
- Saxne T, Palladino MA Jr, Heinegård D, Talal N, Wollheim FA. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum. 1988;31(Suppl 8):1041–1045. - PubMed
- Brennan FM, Chantry D, Jackson AM, Maini RN, Feldmann M. Cytokine production in culture by cells isolated from the synovial membrane. J Autoimmun. 1989;2(Suppl):177–186. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical